Bcl-XL protein levels determine apoptotic index in pancreatic carcinoma

Pancreas

Volumn 30, Issue 4, 2005, Pages 337-342

  Sharma, Jyotika ^a   Srinivasan, Radhika ^a   Majumdar, Siddhartha ^a   Mir, Snober ^a   Radotra, Bishan Dass ^a   Wig, Jai Dev ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Apoptosis; Apoptotic index; Bax; Bcl 2; Bcl Xl; Immunohistochemistry; Pancreatic cancer

Indexed keywords

DNA FRAGMENT; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; BCL2L1 PROTEIN, HUMAN; PROTEIN BCL X; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DENSITOMETRY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; GENETICS; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; UPREGULATION;

ADULT; AGED; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 17844403793     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpa.0000160282.64451.f1     Document Type: Article

References (34)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics 1998. CA Cancer J Clin. 1998;48:6-29.
2. Kern S, Hruban RHB, Hollingsworth MA, et al. A white paper: the product of a pancreas cancer think tank. Cancer Res. 2001;61:4923-4932.
3. Demeure MJ, Doffek KM, Komorowsky RA. Adenocarcinoma of pancreas: detection of occult metastasis in regional lymph nodes by a PCR based assay. Cancer. 1998;83:1328-1334.
4. Chappuis PO, Ghadirian P, Foulkes WD. Role of genetic factors in the etiology of pancreatic adenocarcinoma: an update. Cancer Invest. 2001; 19:65-75.
5. Manning FC, Patierno SR. Apoptosis: inhibitor or instigator of carcinogenesis? Cancer Invest. 1996;14:455-465.
6. Kerr JF, Winterford CM, Harmon BV. Apoptosis, its significance in cancer and cancer therapy. Cancer. 1994;73:2013-2026.
7. Huang Z. Bcl-2 family proteins as targets for anti cancer drug design. Oncogene. 2000;19:6627-6631.
8. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322-1326.
9. Hockenberg DM. Bcl-2 in cancer, development and apoptosis. J Cell Sci. 1994;18:51-55.
10. Chao DT, Korsmeyer SJ. Bcl-2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395-419.
11. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 1997;3:614-620.
12. McDonnell TJ, Beham A, Sarkiss M, et al. Importance of the Bcl-2 family in cell death regulation. Experientia. 1996;52:1008-1017.
13. Antonsson B, Conti F, Ciavatta A, et al. Inhibition of Bax channel forming activity by Bcl-2. Science. 1997;272:370-372.
14. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of Cyt c from mitochondria blocked. Science. 1997;275:1129-1132.
15. Bettaieb A, Dubrez-Daloz L, Launay S, et al. Bcl-2 proteins: targets and tools for chemosensitization of tumor cells. Curr Med Chem Anticanc Agents. 2003;3:307-318.
16. Krajewska M, Moss SF, Krajewski S, et al. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res. 1996;56:2422-2427.
17. Bronner MP, Culin C, Reed JC, et al. The Bcl-2 protooncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol. 1995; 146:20-26.
18. Bubendorf H, Sauter G, Moch H, et al. Prognostic significance of Bcl-2 in clinically localized prostrate cancer. Am J Pathol. 1996;148:1557-1565.
19. Friess H, Lu Z, Graber HU, et al. Bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut. 1998;43:414-421.
20. Evans JD, Cornford PA, Dodson A, et al. Detailed tissue expression of bcl-2, bax, baK and bcl-X in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. Pancreatology. 2001;1:254-262.
21. Campani D, Esposito I, Boggi U, et al. Bcl-2 expression in pancreas development and pancreatic cancer progression. J Pathol. 2001;194:444-450.
22. Miyamoto Y, Hosotani R, Wada M, et al. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X and Mcl-1 expression in pancreatic cancers. Oncology. 1999;56:73-82.
23. L worsens the prognosis in pancreatic cancer. Ann Surg. 1998;228:780-787.
24. Ghaneh P, Kawesha A, Evans JD, et al. Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2002;9:1-11.
25. Makinen K, Hakala T, Lipponen P, et al. Clinical contribution of Bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma. Anticancer Res. 1998;18:615-618.
26. Sinicrope FA, Evans DB, Leach SD, et al. Bcl-2 and p53 expression in respectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res. 1996;2:2015-2022.
27. Sun CY, Wang BL, Hu CQ, et al. Expression of the Bcl-2 gene and its significance in human pancreatic carcinoma. Hepatobiliary Pancreat Dis Int. 2002;1:306-308.
28. Virkajarvi N, Paakko P, Soini Y. Apoptotic index and apoptosis influencing protein Bcl-2, Mcl-1, Bax and caspases 3,6 and 8 in pancreatic cancer. Histopathology. 1998;33:432-439.
29. Nio Y, Iguchi C, Yamasawa K, et al. Apoptosis and expression of Bcl-2 and Bax proteins in invasive ductal carcinoma of the pancreas. Pancreas. 2001;22:230-239.
30. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumors, 5th ed. New York: Wiley-Liss; 1997:87-90.
31. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis. 1997;18:533-537.
32. L can confer a multidrug resistance phenotype. Blood. 1995;86:1903-1910.
33. L by cytotoxic drug exposure confers resistance to ionizing radiation induced internucleosomal DNA fragmentation. Cell Growth Differ. 1995;6:363-370.
34. L is expressed in neuroblastoma cells and modulates chemotherapy induced apoptosis. Cancer Res. 1995; 55:2576-2582.